Premium
Is the effect of atorvastatin 60 mg on stabilization of lipid‐rich plaque equivalent to that of rosuvastatin 10 mg? A serial optical coherence tomography combined with intravascular ultrasound imaging
Author(s) -
Xu Maoen,
Demuyakor Abigail,
Hu Sining,
Liu Huimin,
Zhao Chen,
Chen Tao,
Qin Yuhan,
Xu Yishuo,
Feng Xue,
Zeng Ming,
Weng Ziqian,
Gao Zhanqun,
Hou Jingbo,
Jia Haibo,
Zhang Shuo,
Yu Bo
Publication year - 2021
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.29654
Subject(s) - rosuvastatin , intravascular ultrasound , medicine , atorvastatin , optical coherence tomography , statin , ultrasound , cholesterol , fibrous cap , urology , lipid profile , nuclear medicine , cardiology , gastroenterology , radiology
Objectives This study aimed to compare the effect of atorvastatin 60 (AT60) mg to that of rosuvastatin 10 (RT10) mg on the morphological changes in lipid‐rich plaques (LRPs) and plaque volume, using serial optical coherence tomography (OCT) and intravascular ultrasound imaging (IVUS). Background Intensive lipid lowering therapy by statin provides more clinical benefit compared to that of moderate lipid lowering therapy. Methods Fifty patients who underwent OCT and IVUS at baseline, 6, and 12 months were grouped by statin therapy into the AT60 mg ( n = 27) and RT10 mg ( n = 23) groups. The relationships between absolute and percentage changes in biomarkers and fibrous cap thickness (FCT) during follow‐up were investigated using a simple regression analysis. Results At 6 months, the mean low‐density lipoprotein cholesterol level reduced from 113.5 to 65.5 mg/dl (AT60 mg group) and 100.2 to 72.2 mg/dl (RT10 mg groups). A continuous increase in FCT from baseline to 12 months was observed in both groups ( p < .001, p < .001, respectively). Mean lipid arc significantly decreased in both AT60 mg (189.0 ± 55.9°, 170.9 ± 60.2°, 155.6 ± 50.6°, p < .001) and RT10 mg (160.0 ± 45.6°, 151.2 ± 48.5°, 141.1 ± 52.9°, p = .010) groups. Plaque burden did not change significantly in both groups. Conclusions Lipid‐lowering therapy effect with AT60 mg was equivalent to that of RT10 mg in terms of change in plaque morphology. AT60 mg showed more intensive low‐density lipid cholesterol level reduction compared to RT10 mg while RT10 mg was effective in increasing the high‐density lipid cholesterol level. Both statin therapies could effectively stabilize LRPs.